The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 19, 2022

Filed:

Jan. 10, 2018
Applicants:

Bristol-myers Squibb Company, Princeton, NJ (US);

Five Prime Therapeutics, Inc., South San Francisco, CA (US);

Inventors:

Robert J. Johnston, San Mateo, CA (US);

Andrew Rankin, Redwood City, CA (US);

Arathi Krishnakumar, Chesterfield, NJ (US);

Paul O. Sheppard, Granite Falls, WA (US);

Arvind Rajpal, San Francisco, CA (US);

Assignees:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Five Prime Therapeutics, Inc., Thousand Oaks, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01);
Abstract

Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.


Find Patent Forward Citations

Loading…